Genitourinary Syndrome of Menopause (GSM)

1. Clinical Overview

Summary

Genitourinary Syndrome of Menopause (GSM), formerly termed atrophic vaginitis or vulvovaginal atrophy, is a chronic, progressive condition affecting up to 50% of postmenopausal women.[1,2] Unlike vasomotor symptoms which typically improve with time, GSM persists and worsens without treatment.[3] The condition results from estrogen deficiency causing vaginal epithelial atrophy, loss of rugae, decreased lubrication, altered vaginal microbiome, and elevated pH (> 4.5–5.0).[4]

GSM encompasses vaginal, vulval, and urinary symptoms including vaginal dryness, dyspareunia, vulval irritation, recurrent urinary tract infections (UTIs), urgency, and dysuria.[5] The condition significantly impacts quality of life, sexual function, and intimate relationships, yet remains underdiagnosed due to patient reluctance to report symptoms and clinician failure to ask.[6]

First-line treatment is low-dose vaginal estrogen (estriol cream, estradiol pessaries, estradiol ring), which demonstrates superior efficacy to non-hormonal therapies with minimal systemic absorption and excellent safety profile, including in breast cancer survivors (after specialist discussion).[7,8] Non-hormonal options include vaginal moisturizers, lubricants, ospemifene, and intravaginal DHEA.[9]

Key Facts

• Prevalence: 40–60% of postmenopausal women; 15% of premenopausal women on aromatase inhibitors[1,10]
• Pathophysiology: Estrogen deficiency → epithelial atrophy → ↓ glycogen → ↓ lactobacilli → ↑ vaginal pH (> 5.0)[4]
• Cardinal Symptoms: Vaginal dryness (most common), dyspareunia, recurrent UTIs[5]
• Diagnosis: Clinical; vaginal pH > 4.5; maturation index shows ↑ parabasal cells[11]
• First-line Rx: Vaginal estrogen (estriol 0.5 mg cream or estradiol 10 mcg pessary)[7]
• Safety: Minimal systemic absorption; no endometrial surveillance required; safe in most breast cancer survivors[8,12]
• Natural History: Progressive worsening without treatment (unlike vasomotor symptoms)[3]

Clinical Pearls

"GSM Doesn't Burn Out": Unlike hot flushes that resolve over 2–5 years, GSM is chronic and progressive without treatment.[3]

"pH > 5.0 = GSM": Vaginal pH > 4.5 supports diagnosis; pH > 5.0 is highly specific for estrogen deficiency.[11]

"Ask the Question": 70% of women do not spontaneously report symptoms; direct questioning is essential.[6]

"Vaginal Estrogen ≠ Systemic HRT": Vaginal estrogen preparations result in serum estradiol levels within postmenopausal range; no progestogen or endometrial monitoring required.[12]

"Breast Cancer ≠ Absolute Contraindication": Low-dose vaginal estrogen may be used after discussion with oncology team; benefits often outweigh theoretical risks.[8]

---

2. Epidemiology

Prevalence

Risk Factors

Demographics

• Age: Symptoms typically begin 4–5 years post-menopause; prevalence increases with time[1]
• Geography: Universal; reported across all ethnic groups
• Underdiagnosis: Only 20–25% of symptomatic women seek treatment; 40% believe symptoms are "normal aging"[6]

---

3. Aetiology & Pathophysiology

Molecular Mechanisms of Estrogen Deficiency

Exam Detail: Estrogen Receptor (ER) Distribution:

• Vaginal epithelium: Dense ERα and ERβ expression in basal and parabasal layers[16]
• Urethral epithelium: ERα predominant
• Pelvic floor muscles: ERβ predominant
• Vascular endothelium: Both ERα and ERβ

Estrogen-Mediated Effects:

1. Epithelial Proliferation: Estrogen stimulates maturation of vaginal epithelium through 3–4 cell layers (basal → parabasal → intermediate → superficial)[4]
2. Glycogen Deposition: Estrogen induces glycogen synthesis in intermediate and superficial cells[4]
3. Lactobacillus Colonization: Lactobacilli metabolize glycogen → lactic acid → vaginal pH 3.8–4.5[4]
4. Vascularity: Estrogen promotes angiogenesis; ↑ vaginal blood flow → transudation (lubrication)[16]
5. Collagen/Elastin: Estrogen maintains connective tissue integrity; deficiency → vaginal wall thinning, loss of rugae[16]

Cascade of Estrogen Deficiency

┌─────────────────────────────────────────────────────────────────┐
│         ESTROGEN DEFICIENCY (Menopause)                         │
└─────────────────────┬───────────────────────────────────────────┘
                      │
          ┌───────────┼───────────┐
          ▼           ▼           ▼
    Epithelial   Vascular    Microbiome
    Changes      Changes     Changes
          │           │           │
          ▼           ▼           ▼
  ↓ Proliferation  ↓ Blood flow  ↓ Glycogen
  ↓ Cell layers    ↓ Lubrication ↓ Lactobacilli
  ↑ Parabasal cells              ↑ Vaginal pH (> 5.0)
  Thinning, fragility            ↑ Pathogens (E. coli, etc.)
          │           │           │
          └───────────┼───────────┘
                      ▼
              CLINICAL MANIFESTATIONS
          ┌───────────┼───────────┐
          ▼           ▼           ▼
      VAGINAL     URINARY     SEXUAL
      • Dryness   • UTIs      • Dyspareunia
      • Itch      • Urgency   • ↓ Libido
      • Discharge • Dysuria   • ↓ Arousal
      • Bleeding  • SUI       • Relationship impact
└─────────────────────────────────────────────────────────────────┘

Histological Changes

pH and Microbiome Alterations

Normal Premenopausal State:

• pH 3.8–4.5
• Lactobacillus-dominant (> 90% of microbiota)[4]
• Species: L. crispatus, L. iners, L. gasseri, L. jensenii

GSM State:

• pH 5.0–7.0 (alkaline)[11]
• ↓ Lactobacillus (less than 10% of microbiota)
• ↑ Enteric bacteria (E. coli, Enterococcus)
• ↑ Anaerobes (Gardnerella, Prevotella)
• ↑ UTI susceptibility[5]

Restoration with Vaginal Estrogen:

• pH normalizes to 4.0–5.0 within 2–4 weeks[7]
• Lactobacillus recolonization by 8–12 weeks[18]

---

4. Clinical Presentation

Symptom Domains

GSM presents with vaginal, vulval, sexual, and urinary symptoms.[5] The International Consensus Panel (2014) defined GSM to encompass all these domains, replacing the narrower term "atrophic vaginitis."[2]

A. Vaginal Symptoms

B. Sexual Symptoms

C. Urinary Symptoms

Temporal Pattern

• Onset: Typically 3–5 years post-menopause; earlier with surgical menopause[14]
• Progression: Chronic and progressive; does NOT improve without treatment (cf. vasomotor symptoms)[3]
• Variability: Symptoms may fluctuate but overall trend is worsening
• Sexual activity: Symptoms often worsen with sexual inactivity ("use it or lose it")[20]

Patient Impact

• Quality of Life: Major impact; comparable to chronic diseases (arthritis, diabetes)[6]
• Sexual Function: 60% avoid sexual activity due to dyspareunia[19]
• Relationship Strain: 40% report partner relationship affected[6]
• Psychological: Embarrassment, shame, loss of femininity, depression[6]
• Healthcare Seeking: Only 20–25% seek medical help; majority suffer in silence[6]

---

5. Clinical Examination

General Approach

• Privacy: Ensure adequate privacy, chaperone
• Explanation: Explain findings in non-judgmental language; reassure symptoms are common and treatable
• Consent: Explicit consent for examination

Vulval Examination

Speculum Examination

Exam Detail: Speculum Selection:

• Start with smallest size (Cusco small or Sims)
• Lubricate with water or saline only (avoid gel if taking pH or swabs)
• Warn patient: May be uncomfortable; stop if painful

Findings:

Additional Signs:

• Bleeding on contact: Speculum insertion may cause bleeding (document; differentiate from PMB)
• Vaginal shortening: Apex closer to introitus (advanced GSM, post-RT)
• Pelvic organ prolapse: May coexist (estrogen deficiency weakens supports)

pH Testing

• Method: pH paper (0.5 unit sensitivity) applied to lateral vaginal wall (avoid cervical mucus, blood, semen)
• Normal: 3.8–4.5 (premenopausal)
• GSM: > 4.5 (typically 5.0–7.0)[11]
• Interpretation:
  • pH > 5.0: Highly specific for estrogen deficiency (assuming no infection)[11]
  • pH less than 4.5: GSM unlikely (consider other causes)

Vaginal Maturation Index (VMI)

Indication: Research/specialist settings; not routine practice

Method:

• Lateral vaginal wall scrape (Ayre spatula)
• Cytology: Count 100 cells; classify as parabasal, intermediate, or superficial
• VMI = % parabasal : % intermediate : % superficial

Utility: Confirms estrogen deficiency; monitors treatment response; not required for diagnosis

---

6. Differential Diagnosis

Vulvovaginal Conditions

Urinary Symptoms

• Recurrent UTI: MSU culture; consider imaging if complicated
• Overactive bladder (OAB): Urgency/frequency without dysuria; bladder diary
• Interstitial cystitis: Sterile pyuria; cystoscopy (Hunner's lesions, glomerulations)
• Urethral syndrome: Dysuria, -ve cultures; urethral diverticulum (MRI)

Dyspareunia

• Vulvodynia/provoked vestibulodynia: Cotton-swab test; younger age; no atrophic changes
• Vaginismus: Involuntary muscle spasm; psychological component
• Pelvic floor dysfunction: Tender pelvic floor on examination
• Endometriosis: Deep dyspareunia (not superficial); pelvic pain

---

7. Investigations

First-Line (Usually None Required)

GSM is a clinical diagnosis in typical postmenopausal women with characteristic symptoms and examination findings.[21]

Supportive Investigations (If Diagnostic Uncertainty)

When to Investigate Postmenopausal Bleeding (PMB)

Red Flag: Any vaginal bleeding > 12 months post-menopause requires investigation (endometrial cancer risk ~10%).[22]

GSM-Related Bleeding:

• Contact bleeding: Occurs during examination, intercourse
• Minimal volume: Spotting, streaking
• Source: Visible atrophic vaginal/cervical erosion on speculum examination

Investigations for PMB:

Management:

• If ET less than 4 mm + visible atrophic source: Treat with vaginal estrogen; reassess in 3 months
• If ET ≥4 mm: Proceed to biopsy ± hysteroscopy
• If bleeding persists despite treatment: Repeat imaging/biopsy

---

8. Management

Treatment Algorithm

┌──────────────────────────────────────────────────────────────────────┐
│                   GSM / ATROPHIC VAGINITIS MANAGEMENT                │
├──────────────────────────────────────────────────────────────────────┤
│                                                                      │
│  STEP 1: NON-HORMONAL (First-line if mild, or patient preference)   │
│  ┌────────────────────────────────────────────────────────────────┐ │
│  │ • Vaginal moisturizers (Replens, Yes VM, Hyaluronic acid gel) │ │
│  │   - Use 2–3× per week (not just with intercourse)              │ │
│  │   - Effect lasts 2–3 days; maintains hydration                 │ │
│  │ • Lubricants during intercourse (water-based: Sylk, Yes, KY)  │ │
│  │   - Use liberally; reapply as needed                           │ │
│  │   - Avoid oil-based (damages condoms) or irritants             │ │
│  │ • Lifestyle: Regular sexual activity; adequate hydration       │ │
│  │ • Efficacy: 30–50% symptom improvement (inferior to estrogen)  │ │[9]
│  └────────────────────────────────────────────────────────────────┘ │
│           │                                                           │
│           │ If inadequate response (moderate-severe symptoms)         │
│           ▼                                                           │
│                                                                      │
│  STEP 2: VAGINAL ESTROGEN (First-line for moderate-severe GSM)      │
│  ┌────────────────────────────────────────────────────────────────┐ │
│  │ OPTIONS (all equivalent efficacy; patient choice):             │ │
│  │                                                                │ │
│  │ A. ESTRADIOL PESSARY (Vagifem 10 mcg)                          │ │
│  │    - 1 pessary daily × 14 days, then 2× per week (long-term)  │ │
│  │    - Most commonly used; discrete                              │ │
│  │                                                                │ │
│  │ B. ESTRIOL CREAM (Ovestin 0.5 mg/g; 1 g = 0.5 mg estriol)     │ │
│  │    - 1 applicator (0.5 mg) daily × 14–21 days                 │ │
│  │    - Then 2× per week (maintenance)                            │ │
│  │    - Messy; some prefer for lubricant effect                   │ │
│  │                                                                │ │
│  │ C. ESTRADIOL VAGINAL RING (Estring 7.5 mcg/24h)                │ │
│  │    - Insert into upper vagina; replace every 3 months          │ │
│  │    - Convenient; continuous release                            │ │
│  │    - Patient/partner may feel ring during intercourse          │ │
│  │                                                                │ │
│  │ EFFICACY: 80–90% symptom improvement within 4–12 weeks         │ │[7]
│  │ SAFETY:                                                        │ │
│  │  • Minimal systemic absorption (serum E2 remains in           │ │
│  │    postmenopausal range)                                       │ │[12]
│  │  • No endometrial surveillance required                        │ │
│  │  • No progestogen needed                                       │ │
│  │  • Safe long-term use (years)                                  │ │
│  │  • Breast cancer: Discuss with oncology; often considered safe │ │[8]
│  └────────────────────────────────────────────────────────────────┘ │
│           │                                                           │
│           │ If contraindication to estrogen or patient refuses       │
│           ▼                                                           │
│                                                                      │
│  STEP 3: NON-ESTROGEN PRESCRIPTION OPTIONS                           │
│  ┌────────────────────────────────────────────────────────────────┐ │
│  │ A. OSPEMIFENE (Senshio 60 mg oral, once daily)                 │ │
│  │    - Selective Estrogen Receptor Modulator (SERM)             │ │
│  │    - Estrogen agonist on vagina, antagonist on breast/uterus  │ │
│  │    - Efficacy: Moderate (inferior to vaginal estrogen)         │ │[23]
│  │    - SE: Hot flushes, VTE risk (CI if h/o VTE)                │ │
│  │    - Indicated if vaginal route declined                       │ │
│  │                                                                │ │
│  │ B. INTRAVAGINAL DHEA (Prasterone 6.5 mg pessary, daily)       │ │
│  │    - Converted locally to estrogen + testosterone              │ │
│  │    - Licensed in USA/Canada; limited availability UK            │ │
│  │    - Efficacy: Equivalent to vaginal estradiol                 │ │[24]
│  │    - Useful if estrogen contraindicated (theoretical)          │ │
│  │                                                                │ │
│  │ C. VAGINAL LASER THERAPY (CO2 or Er:YAG laser)                 │ │
│  │    - Mechanism: Thermal stimulation → neocollagenesis          │ │
│  │    - 3 sessions, 4–6 week intervals; annual top-up             │ │
│  │    - Evidence: RCTs show modest benefit (≈ moisturizers)       │ │[25]
│  │    - NOT superior to vaginal estrogen                          │ │
│  │    - Expensive; not NHS-funded; not NICE-approved              │ │
│  │    - Consider if all else fails                                │ │
│  └────────────────────────────────────────────────────────────────┘ │
│                                                                      │
│  STEP 4: SYSTEMIC HRT (If concomitant vasomotor symptoms)           │
│  ┌────────────────────────────────────────────────────────────────┐ │
│  │ • Systemic estrogen treats hot flushes but often INSUFFICIENT  │ │
│  │   for GSM                                                      │ │
│  │ • 10–25% on systemic HRT still have GSM symptoms               │ │[26]
│  │ • May need to ADD vaginal estrogen to systemic HRT             │ │
│  │ • No additional progestogen required if adding vaginal estrogen│ │
│  └────────────────────────────────────────────────────────────────┘ │
│                                                                      │
│  ADJUNCTS FOR RECURRENT UTI                                          │
│  ┌────────────────────────────────────────────────────────────────┐ │
│  │ • Vaginal estrogen: ↓ UTI recurrence by ~50%                   │ │[27]
│  │ • Cranberry products: Weak evidence; may help some             │ │
│  │ • D-mannose: Emerging evidence; 1.5–2 g daily                  │ │
│  │ • Prophylactic antibiotics: If above fail (e.g., nitrofurantoin│ │
│  │   50 mg nocte or trimethoprim 100 mg nocte)                    │ │
│  └────────────────────────────────────────────────────────────────┘ │
│                                                                      │
└──────────────────────────────────────────────────────────────────────┘

Vaginal Estrogen: Detailed Prescribing

Exam Detail: Formulations and Dosing:

Systemic Absorption:

• Serum estradiol remains within postmenopausal range (less than 150 pmol/L)[12]
• No clinically significant systemic effects at standard doses
• No endometrial proliferation at licensed doses[12]

Endometrial Safety:

• No progestogen required (unlike systemic HRT)[12]
• No routine endometrial surveillance needed (TVUS, biopsy)[21]
• If PMB occurs: Investigate as per standard PMB protocol (TVUS ± biopsy)[22]
• Higher doses (e.g., estriol 0.5 mg daily long-term): Possible endometrial stimulation; some advocate annual TVUS (controversial)[21]

Duration of Treatment:

• GSM is chronic; treatment typically lifelong[3]
• No arbitrary discontinuation; reassess annually
• Attempts to stop often result in symptom recurrence within weeks to months

Treatment Response:

• Symptom improvement: 4–12 weeks (dryness improves first; dyspareunia may take 2–3 months)[7]
• pH normalization: 2–4 weeks[18]
• Epithelial maturation: 4–8 weeks (VMI shift)[18]
• If no response by 12 weeks: Check adherence; consider alternative diagnosis; increase frequency (daily vs. 2×/wk)

Special Populations

Breast Cancer Survivors

Key Principles:

• GSM prevalence: 50–60% (chemotherapy, tamoxifen, aromatase inhibitors)[13]
• Vaginal estrogen often avoided by oncologists due to theoretical concerns (estrogen-sensitive tumor)
• However: Evidence suggests minimal systemic absorption and no increased recurrence risk with low-dose vaginal estrogen[8]

Management Approach:

1. First-line: Non-hormonal (moisturizers, lubricants)
2. Second-line: Discuss with oncology team
   • Aromatase inhibitor users: Vaginal estrogen may be acceptable (especially after 2–5 years)[8]
   • Tamoxifen users: Less clear; theoretical concern (tamoxifen is ER antagonist; exogenous estrogen may negate effect)
3. Third-line: Ospemifene (SERM; vaginal agonist, breast antagonist)[23] or DHEA[24]
4. Emerging: Vaginal laser (evidence limited)[25]

Evidence:

• Le Ray et al. (2012): No ↑ recurrence with vaginal estrogen in breast cancer survivors[8]
• Cochrane review (2016): Insufficient evidence of harm, but limited data[28]

Contraindications to Vaginal Estrogen

Absolute:

• Active or recent (within 1 year) estrogen-dependent malignancy (controversial; see above)
• Undiagnosed vaginal bleeding (investigate first)

Relative (Specialist discussion):

• History of breast cancer (especially recent, ER+)
• History of endometrial cancer (discuss with gynae-oncology)
• Active VTE (though systemic absorption minimal)
• Severe liver disease

---

9. Complications

Of Untreated GSM

Of Treatment

Vaginal Estrogen:

• Common (> 1%): Mild vaginal bleeding (usually settles); breast tenderness (rare at low doses); vaginal discharge
• Rare: Endometrial proliferation (if excessive dose/duration); systemic effects (minimal with standard doses)
• Serious: None reported at licensed doses

Ospemifene:

• Hot flushes (7%), VTE (rare, ~1/1000/year), endometrial thickening (requires monitoring)[23]

Laser Therapy:

• Pain during treatment, vaginal discharge, rare vaginal burns/scarring[25]

---

10. Prognosis & Outcomes

Natural History (Untreated)

• Progression: Chronic, progressive worsening over years[3]
• No spontaneous improvement (unlike vasomotor symptoms which resolve over 2–5 years)
• Severe atrophy: Vaginal stenosis, labial fusion may develop after 10–15 years[17]

With Treatment

Long-Term Considerations

• Treatment duration: Often lifelong; symptoms recur if stopped[3]
• Adherence: 30–40% discontinue treatment (often due to embarrassment, messiness of creams, cost)[29]
• Patient education: Essential to emphasize chronic nature, safety, need for long-term use

---

11. Prevention

Modifiable Risk Factors

• Smoking cessation: Reduces anti-estrogenic effects
• Regular sexual activity: Maintains vaginal blood flow and elasticity ("use it or lose it")[20]
• Early intervention: Treat symptoms early to prevent progression

Role of HRT in Perimenopause

• Systemic HRT in perimenopause may delay GSM onset, but many women still develop symptoms[26]
• Vaginal estrogen often needed even in women on systemic HRT

---

12. Evidence & Guidelines

Key Guidelines

Landmark Evidence

1. Cochrane Review (Lethaby et al., 2016): Vaginal estrogen superior to placebo for all GSM symptoms; estriol, estradiol, conjugated estrogens equally effective.[7]

2. Suckling et al. (2006): Local estrogen for vaginal atrophy: Systematic review confirmed efficacy and safety.[33]

3. Rahn et al. (2014): Vaginal estrogen for GSM: Serum estradiol remains in postmenopausal range; no endometrial proliferation at licensed doses.[12]

4. Perrotta et al. (2008): Vaginal estrogen reduces recurrent UTI by 36–50% in postmenopausal women.[27]

5. Le Ray et al. (2012): No increased breast cancer recurrence with vaginal estrogen in survivors.[8]

6. Constantine et al. (2015): Ospemifene efficacy for moderate-severe dyspareunia (SERM).[23]

7. Labrie et al. (2016): Intravaginal DHEA (prasterone) effective for dyspareunia and vaginal dryness.[24]

8. Pitsouni et al. (2017): Systematic review of vaginal laser therapy: Modest short-term benefit, insufficient long-term data.[25]

---

13. Examination Focus (MRCOG Part 3)

Viva Questions and Model Answers

Exam Detail: Q1: A 58-year-old postmenopausal woman presents with vaginal dryness and dyspareunia. How would you manage her?

Model Answer:

"I would take a focused history including:

• Menopause age, duration of symptoms, impact on quality of life and sexual function
• Current medications (especially aromatase inhibitors, tamoxifen)
• Vasomotor symptoms (if present, may benefit from systemic HRT)
• Exclude red flags: postmenopausal bleeding, unilateral vulval lesion

I would perform a speculum examination (with consent) to confirm GSM: pale, dry vaginal mucosa, loss of rugae, petechiae, raised pH > 4.5, and exclude other pathology (lichen sclerosus, malignancy).

Management would follow a stepwise approach:

1. Non-hormonal options (if mild or patient preference): vaginal moisturizers 2–3× per week, lubricants during intercourse
2. Vaginal estrogen (first-line for moderate-severe): estradiol pessaries (Vagifem 10 mcg) daily for 14 days then twice weekly, OR estriol cream (Ovestin 0.5 mg) same regimen, OR estradiol ring (Estring) 3-monthly
3. Reassure regarding safety: minimal systemic absorption, no progestogen needed, no routine endometrial monitoring, safe for long-term use

I would review at 3 months to assess response. If inadequate, check adherence, consider increasing frequency to daily, or trial alternative formulation. If still no improvement, consider ospemifene or refer to specialist menopause clinic."

---

Q2: Why is vaginal estrogen considered safe without progestogen?

Model Answer:

"Vaginal estrogen at licensed low doses (estradiol 10 mcg, estriol 0.5 mg) results in minimal systemic absorption. Studies show serum estradiol levels remain within the postmenopausal range (10–25 pmol/L), far below the threshold for endometrial proliferation.

Key evidence:

• Rahn et al. (2014): No endometrial proliferation detected on biopsy after 1 year of vaginal estradiol 10 mcg
• Cochrane review (2016): No increased risk of endometrial hyperplasia or carcinoma

Therefore, no progestogen opposition is required, and no routine endometrial surveillance (TVUS or biopsy) is recommended by NICE, BMS, and NAMS guidelines.

Exception: If higher doses used (e.g., daily estriol 0.5 mg long-term), some advocate annual TVUS, though evidence is limited. Any postmenopausal bleeding requires investigation irrespective of vaginal estrogen use."

---

Q3: A patient on an aromatase inhibitor for breast cancer has severe GSM. How would you manage this?

Model Answer:

"This is a challenging scenario requiring multidisciplinary discussion with the patient's oncology team.

Background:

• Aromatase inhibitors profoundly suppress estrogen → 70–80% develop GSM, often severe
• Oncologists often avoid estrogen due to theoretical risk of cancer recurrence
• However, vaginal estrogen has minimal systemic absorption and evidence suggests no increased recurrence risk

Management approach:

1. First-line: Non-hormonal therapies (vaginal moisturizers, lubricants) – but often insufficient
2. Discuss with oncology: Consider low-dose vaginal estrogen (estradiol 10 mcg pessaries or estriol cream)
   • Le Ray et al. (2012): No increased recurrence in breast cancer survivors using vaginal estrogen
   • BMS (2018): May be acceptable after discussion, especially > 2–5 years post-treatment
3. Alternatives if estrogen declined:
   • Ospemifene (SERM; vaginal agonist, breast antagonist) – limited data in breast cancer
   • Intravaginal DHEA (prasterone) – converted locally; theoretical only
   • Vaginal laser therapy – modest evidence, expensive, not NHS-funded

Shared decision-making is key: discuss risks/benefits, document discussion, obtain oncology input."

---

Q4: What is the difference between GSM and bacterial vaginosis?

Model Answer:

"Both present with altered vaginal pH > 4.5 and altered discharge, but they differ in etiology, symptoms, examination, and management:

Note: Postmenopausal women with GSM may have secondary BV (raised pH → loss of lactobacilli → overgrowth). Treat BV with antibiotics, then vaginal estrogen to restore normal microbiome."

---

Q5: Describe the pathophysiology of recurrent UTIs in GSM.

Model Answer:

"GSM predisposes to recurrent UTIs through multiple mechanisms:

1. Vaginal pH elevation (5.0–7.0): Loss of estrogen → ↓ epithelial glycogen → ↓ lactobacilli → loss of lactic acid production → ↑ pH
2. Loss of lactobacillus protection: Lactobacilli produce lactic acid, hydrogen peroxide, and bacteriocins that inhibit uropathogens (especially E. coli)
3. Colonization by uropathogens: Elevated pH favors colonization of vagina/introitus by enteric bacteria (E. coli, Klebsiella, Enterococcus) → reservoir for bladder infection
4. Urethral atrophy: Estrogen deficiency causes urethral epithelial thinning, loss of mucosal coaptation, ↑ bacterial adherence
5. Reduced bladder defenses: Estrogen normally enhances urothelial integrity and immune response; deficiency ↓ defenses

Evidence:

• Vaginal estrogen therapy restores vaginal pH, promotes lactobacillus recolonization, and reduces UTI recurrence by ~50% (Perrotta et al., 2008)
• NICE and EAU guidelines recommend vaginal estrogen for recurrent UTI prevention in postmenopausal women

Clinical implication: In postmenopausal women with recurrent UTI, vaginal estrogen is first-line prophylaxis (superior to continuous antibiotics in this population)."

---

14. Patient/Layperson Explanation

What is Genitourinary Syndrome of Menopause (GSM)?

GSM (also called atrophic vaginitis) is a very common condition that happens after menopause when your body produces less estrogen (the female hormone). This causes the tissues of the vagina and vulva (external genital area) to become thinner, drier, and less elastic.

How Common is It?

About half of all postmenopausal women experience GSM. Many women don't talk about it because of embarrassment, but it's a normal result of menopause and very treatable.

What Are the Symptoms?

• Vaginal dryness (the most common symptom)
• Pain during sex (called dyspareunia)
• Itching or burning in the vaginal area
• Unusual discharge (thin and watery)
• Needing to urinate more often or urgently
• Repeated urine infections
• Light bleeding after sex or during examination (because the tissues are fragile)

Does It Get Better on Its Own?

No. Unlike hot flushes which usually improve after a few years, vaginal dryness and GSM symptoms get worse with time if not treated. This is why it's important to seek help.

How is GSM Diagnosed?

Your doctor will ask about your symptoms and may examine you (with your permission). The examination may show pale, dry vaginal tissues. Usually, no tests are needed – the diagnosis is based on your symptoms and examination.

How is GSM Treated?

1. Non-Hormonal Options (for mild symptoms or if you prefer to avoid hormones):

• Vaginal moisturizers (such as Replens or Yes VM): Use 2–3 times per week to keep the vagina hydrated
• Lubricants (such as Sylk, Yes, or KY Jelly): Use during sex to reduce friction and discomfort
• Regular sexual activity: This helps maintain blood flow and elasticity

2. Vaginal Estrogen (the most effective treatment):

• Small amounts of estrogen are placed directly into the vagina using creams, tablets (pessaries), or a soft ring
• Examples:
  • "Vagifem (small tablet inserted with an applicator): 1 tablet daily for 2 weeks, then twice a week"
  • "Ovestin cream: Applied with an applicator; 1 dose daily for 2 weeks, then twice a week"
  • "Estring (soft ring): Inserted into the vagina and replaced every 3 months"

How Well Does Vaginal Estrogen Work?

• 8 out of 10 women notice significant improvement within 4–12 weeks
• Symptoms usually start improving within a few weeks

3. Other Options (if vaginal estrogen is not suitable):

• Ospemifene (Senshio): A tablet taken by mouth that acts like estrogen in the vagina but not in the breast or womb
• Vaginal DHEA: Another hormone treatment (not widely available in the UK)
• Laser therapy: A new treatment where a laser is used to stimulate the vaginal tissues (expensive, not available on the NHS, and evidence is limited)

Is Vaginal Estrogen Safe?

Yes, vaginal estrogen is very safe. Here's why:

• Only a tiny amount of estrogen is absorbed into your body (much less than HRT tablets)
• Your blood estrogen levels stay in the normal postmenopausal range
• You don't need extra hormones to protect the lining of the womb (unlike HRT tablets)
• You don't need regular scans or check-ups of the womb lining
• It's safe to use for many years (GSM is a long-term condition)

What About Breast Cancer?

Many women worry about using estrogen if they have had breast cancer. The good news is:

• Vaginal estrogen is absorbed in such small amounts that it's often considered safe even in women with a history of breast cancer
• Your doctor will discuss this with your cancer specialist to make sure it's right for you
• Alternatives like moisturizers, lubricants, or ospemifene can be used if needed

How Long Will I Need Treatment?

GSM is a chronic (long-term) condition. Most women need to continue treatment for as long as symptoms persist, which is often for the rest of their lives. If you stop treatment, symptoms usually come back within weeks to months.

What Happens If GSM is Not Treated?

Without treatment, symptoms usually get worse over time. This can lead to:

• Ongoing discomfort and pain
• Difficulty or inability to have sex
• Repeated urine infections
• Relationship problems
• Reduced quality of life

Don't Be Embarrassed – Seek Help!

GSM is very common, and there are excellent treatments available. If you're experiencing any of these symptoms, please speak to your GP or practice nurse. You don't have to suffer in silence.

---

15. References

Guidelines

1. Portman DJ, Gass ML. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Menopause. 2014;21(10):1063-1068. PMID: 25160739 DOI: 10.1097/GME.0000000000000329

2. Parish SJ, Nappi RE, Krychman ML, et al. Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy. Int J Womens Health. 2013;5:437-447. PMID: 23935388 DOI: 10.2147/IJWH.S44579

3. Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med. 2009;6(8):2133-2142. PMID: 19493278 DOI: 10.1111/j.1743-6109.2009.01335.x

4. Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc. 2010;85(1):87-94. PMID: 20042564 DOI: 10.4065/mcp.2009.0413

5. Raz R, Gennesin Y, Wasser J, et al. Recurrent urinary tract infections in postmenopausal women. Clin Infect Dis. 2000;30(1):152-156. PMID: 10619744 DOI: 10.1086/313596

6. Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med. 2013;10(7):1790-1799. PMID: 23679050 DOI: 10.1111/jsm.12190

7. Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016;2016(8):CD001500. PMID: 27577677 DOI: 10.1002/14651858.CD001500.pub3

8. Le Ray I, Dell'Aniello S, Bonnetain F, Azoulay L, Suissa S. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study. Breast Cancer Res Treat. 2012;135(2):603-609. PMID: 22864769 DOI: 10.1007/s10549-012-2198-y

9. Edwards D, Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climacteric. 2016;19(2):151-161. PMID: 26581580 DOI: 10.3109/13697137.2015.1124259

10. Loibl S, Lintermans A, Dieudonné AS, Neven P. Management of menopausal symptoms in breast cancer patients. Maturitas. 2011;68(2):148-154. PMID: 21167667 DOI: 10.1016/j.maturitas.2010.11.013

11. Bachmann GA, Nevadunsky NS. Diagnosis and treatment of atrophic vaginitis. Am Fam Physician. 2000;61(10):3090-3096. PMID: 10839558

12. Rahn DD, Carberry C, Sanses TV, et al. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol. 2014;124(6):1147-1156. PMID: 25415166 DOI: 10.1097/AOG.0000000000000526

13. Baumgart J, Nilsson K, Evers AS, Kallak TK, Poromaa IS. Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer. Menopause. 2013;20(2):162-168. PMID: 22990755 DOI: 10.1097/gme.0b013e31826560da

14. Shifren JL, Gass ML. The North American Menopause Society recommendations for clinical care of midlife women. Menopause. 2014;21(10):1038-1062. PMID: 25225714 DOI: 10.1097/GME.0000000000000319

15. Nappi RE, Kokot-Kierepa M. Vaginal Health: Insights, Views & Attitudes (VIVA) – results from an international survey. Climacteric. 2012;15(1):36-44. PMID: 22168244 DOI: 10.3109/13697137.2011.647840

16. Hodgins MB, Spike RC, Mackie RM, MacLean AB. An immunohistochemical study of androgen, oestrogen and progesterone receptors in the vulva and vagina. Br J Obstet Gynaecol. 1998;105(2):216-222. PMID: 9501790 DOI: 10.1111/j.1471-0528.1998.tb10055.x

17. Pastore LM, Carter RA, Hulka BS, Wells E. Self-reported urogenital symptoms in postmenopausal women: Women's Health Initiative. Maturitas. 2004;49(4):292-303. PMID: 15531125 DOI: 10.1016/j.maturitas.2004.06.019

18. Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas. 1996;23(3):259-263. PMID: 8794418 DOI: 10.1016/0378-5122(95)00955-8

19. Goldstein AT, Pukall CF, Brown C, Bergeron S, Stein A, Kellogg-Spadt S. Vulvodynia: Assessment and Treatment. J Sex Med. 2016;13(4):572-590. PMID: 27045258 DOI: 10.1016/j.jsxm.2016.01.020

20. Leiblum S, Bachmann G, Kemmann E, Colburn D, Swartzman L. Vaginal atrophy in the postmenopausal woman. The importance of sexual activity and hormones. JAMA. 1983;249(16):2195-2198. PMID: 6834616 DOI: 10.1001/jama.1983.03330400041024

21. National Institute for Health and Care Excellence. Menopause: diagnosis and management (NG23). 2015, updated 2019. www.nice.org.uk/guidance/ng23

22. Clarke MA, Long BJ, Del Mar Morillo A, Arbyn M, Bakkum-Gamez JN, Wentzensen N. Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women: A Systematic Review and Meta-analysis. JAMA Intern Med. 2018;178(9):1210-1222. PMID: 30083701 DOI: 10.1001/jamainternmed.2018.2820

23. Constantine GD, Simon JA, Pickar JH, et al. The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy. Menopause. 2017;24(4):409-416. PMID: 27997449 DOI: 10.1097/GME.0000000000000786

24. Labrie F, Archer DF, Koltun W, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2016;23(3):243-256. PMID: 26731686 DOI: 10.1097/GME.0000000000000571

25. Pitsouni E, Grigoriadis T, Falagas ME, Salvatore S, Athanasiou S. Laser therapy for the genitourinary syndrome of menopause. A systematic review and meta-analysis. Maturitas. 2017;103:78-88. PMID: 28778336 DOI: 10.1016/j.maturitas.2017.06.029

26. Sturdee DW, Panay N. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric. 2010;13(6):509-522. PMID: 20883118 DOI: 10.3109/13697137.2010.522875

27. Perrotta C, Aznar M, Mejia R, Albert X, Ng CW. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane Database Syst Rev. 2008;(2):CD005131. PMID: 18425910 DOI: 10.1002/14651858.CD005131.pub2

28. Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab. 2010;95(7 Suppl 1):s1-s66. PMID: 20566620 DOI: 10.1210/jc.2009-2509

29. Simon JA, Kokot-Kierepa M, Goldstein J, Nappi RE. Vaginal health in the United States: results from the Vaginal Health: Insights, Views & Attitudes survey. Menopause. 2013;20(10):1043-1048. PMID: 23571527 DOI: 10.1097/GME.0b013e318287342d

30. British Menopause Society. BMS consensus statement: the management of genitourinary syndrome of menopause. 2018. https://thebms.org.uk/publications/consensus-statements/

31. The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976-992. PMID: 32852449 DOI: 10.1097/GME.0000000000001609

32. Baber RJ, Panay N, Fenton A; IMS Writing Group. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109-150. PMID: 26872610 DOI: 10.3109/13697137.2015.1129166

33. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2006;(4):CD001500. PMID: 17054136 DOI: 10.1002/14651858.CD001500.pub2

---